Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.
He also holds stock options for 60,000 shares at an exercise price of $41.75 expiring on 10/01/2034 and 31,500 shares at $29.18 expiring on 02/17/2035. These options vest monthly over time, following initial partial vesting completed in January 2026.
The Vanguard Group reported beneficial ownership of 3,570,401 shares of Vera Therapeutics Inc. common stock, representing 5.03% of the outstanding class as of the event date. All shares are held with shared voting and dispositive power through Vanguard-managed client accounts.
Vanguard reports shared voting power over 489,258 shares and shared dispositive power over the full 3,570,401 shares, with no sole voting or dispositive authority. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics.
Vera Therapeutics, Inc. reported a leadership change, stating that Jason Carter will no longer serve as the company’s Chief Legal Officer, effective December 24, 2025. The change was disclosed as an officer departure under a current report, with no additional details provided about his future role or any replacement.
Vera Therapeutics’ Chief Regulatory Officer reported an option exercise and share sale. On December 15, 2025, the officer exercised a stock option to buy 10,000 shares of Class A common stock at $15.53 per share, then sold 10,000 shares of Class A common stock in the open market at a weighted average price of $50.0767 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, the officer directly owned 22,500 shares of Class A common stock and held 245,000 stock options directly.
Vera Therapeutics, Inc. reported an insider share purchase by a director. On 12/11/2025, the reporting person bought 5,882 shares of Class A common stock at $42.5 per share and now directly holds 5,882 shares.
The filing also describes large indirect holdings through investment funds. Longitude Prime Fund, L.P. holds 1,797,619 shares and Longitude Venture Partners IV, L.P. holds 3,596,593 shares. The reporting person, related general partner entities and another managing member may be deemed to share voting and dispositive power over these fund-held shares, while each disclaims beneficial ownership except to the extent of their pecuniary interests.
Vera Therapeutics is offering $200,000,000 of its Class A common stock in a primary public offering, and has granted underwriters an option to buy up to an additional $30,000,000 of shares. The company plans to use the cash, together with existing funds and its Oxford loan facility, to fund the potential commercial launch of its lead drug atacicept for IgA nephropathy, expand atacicept into new clinical indications, and support general corporate purposes such as working capital and capital spending.
Vera is a late clinical-stage biotechnology company focused on serious immunological diseases. Atacicept has shown positive Phase 2b results in IgA nephropathy, a pivotal Phase 3 trial has completed enrollment, and a Biologics License Application was submitted to the FDA through the Accelerated Approval Program on November 7, 2025. Management believes proceeds from this deal, combined with existing resources, will be sufficient to fund projected operating requirements through a potential 2026 U.S. launch of atacicept in IgA nephropathy, if approved, but investors face immediate dilution, no expected dividends, and risks around market liquidity and broad management discretion over how proceeds are spent.
Vera Therapeutics, Inc. (VERA) reported a stock option grant to a director on 11/25/2025. The filing shows a stock option to purchase 25,000 shares of Class A common stock at an exercise price of $29.43 per share, expiring on 11/24/2035.
The option will vest monthly over a three-year period, as long as the director continues to serve through each vesting date. The filing also states that all shares subject to the option will vest in full if there is a change in control, provided the director remains in continuous service through the date of that change in control.
Vera Therapeutics, Inc. (VERA) reported a new insider status update showing that the reporting person, identified as a director of the company, currently has no securities beneficially owned. This Form 3 filing establishes their position as an insider under securities rules without indicating any ownership of Vera Therapeutics stock or derivative securities at this time.
Vera Therapeutics, Inc. announced that its board of directors has appointed James R. Meyers as a Class II director, effective immediately. His initial term will run until the company’s 2026 annual meeting of stockholders, and he has also been appointed to the board’s Audit Committee.
Upon joining the board, Mr. Meyers received a nonstatutory stock option to purchase 25,000 shares of Class A common stock, vesting monthly over three years under the company’s non-employee director compensation policy. He will receive an annual cash retainer of $40,000 for board service and $10,000 for Audit Committee service, pro-rated for 2025. Beginning with the 2026 annual meeting, he will be eligible for an annual option grant for up to the lesser of 14,000 shares or options with a grant date fair value of not more than $400,000, subject to standard vesting tied to continued service.
Vera Therapeutics (VERA) Chief Legal Officer reports share sale. On 11/21/2025, the company’s Chief Legal Officer sold 3,864 shares of Class A common stock in a single reported transaction. The shares were sold at a weighted-average price of $27.8204, with individual trades executed between $27.19 and $28.035.
According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this transaction, the officer beneficially owns 49,136 shares of Vera Therapeutics common stock, held directly.